PT-141 (Bremelanotide): What the Evidence Really Shows

PT-141 is the development code of bremelanotide, a synthetic cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. It is frequently discussed online with confident claims. This review separates what controlled trials established from what remains speculation.

Mechanism under study

Bremelanotide is a non-selective agonist of melanocortin receptors, with notable activity at MC4R and MC3R in the central nervous system and at MC1R, which governs pigmentation. Unlike phosphodiesterase-5 inhibitors, which act on blood flow, it is thought to act on hypothalamic pathways involved in sexual motivation. The precise downstream circuitry in humans is still not fully mapped.

State of the human evidence

The key data come from the two RECONNECT phase 3 trials in premenopausal women with hypoactive sexual desire disorder, published in 2019. Compared with placebo, bremelanotide produced statistically significant but modest improvements in desire scores and reductions in related distress. It did not significantly increase the number of satisfying sexual events, one of the original co-primary endpoints.

Data in men, in postmenopausal women and for any other indication remain limited to small or early-phase studies. Claims of broader benefits are not supported by confirmatory trials.

Risks and adverse effects

• Nausea was the most frequent adverse event in trials, affecting a large share of participants, sometimes with vomiting.
• Flushing, headache and injection-site reactions were also common.
• Transient increases in blood pressure and decreases in heart rate were observed; the approved label restricts use in people with uncontrolled hypertension or cardiovascular disease.
• Focal skin hyperpigmentation, linked to MC1R activity, was reported with repeated exposure.

Limitations of the evidence

Trials were relatively short, focused on a specific population and relied on self-reported scales. Long-term safety data are limited, and effect sizes were small relative to placebo. These constraints matter when interpreting any extrapolation beyond the approved setting.

Regulatory status by region

• United States: approved by the FDA in 2019 (brand Vyleesi) as a prescription medicine for acquired, generalised hypoactive sexual desire disorder in premenopausal women.
• European Union and United Kingdom: no marketing authorisation from the EMA or the MHRA; it is not an approved medicine there.
• Research-grade PT-141 is not the approved product in any jurisdiction and is not intended for human use.

Bottom line

Bremelanotide is a genuine example of a melanocortin peptide that reached approval, but its proven benefit is modest and confined to one indication in one market. For the molecule's history and laboratory background, see our PT-141 research profile.